These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 3476980)

  • 21. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.
    Gogolak VV
    Pharmacoepidemiol Drug Saf; 2003; 12(3):249-52. PubMed ID: 12733479
    [No Abstract]   [Full Text] [Related]  

  • 23. [Seventh French Drug Surveillance Seminar. Caen, 21-22 November 1985].
    Therapie; 1986; 41(5):323-84. PubMed ID: 3810518
    [No Abstract]   [Full Text] [Related]  

  • 24. [Eighth French Drug Surveillance Seminar. Paris, 23-24 October 1986].
    Therapie; 1987; 42(4):331-410. PubMed ID: 3686465
    [No Abstract]   [Full Text] [Related]  

  • 25. [Is imputation in drug surveillance reliable?].
    Girard M
    Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
    [No Abstract]   [Full Text] [Related]  

  • 26. Active reporting scheme: an example to evaluate specific adverse drug reactions.
    Pini LA; Sternieri E
    Acta Physiol Hung; 1990; 75 Suppl():237-8. PubMed ID: 2371875
    [No Abstract]   [Full Text] [Related]  

  • 27. International monitoring for adverse drug reactions of long latency.
    Fletcher AP; Griffin JP
    Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771
    [No Abstract]   [Full Text] [Related]  

  • 28. How should we react to adverse drug reactions?
    Ferner RE; Beard K
    Postgrad Med J; 2011 Feb; 87(1024):81-2. PubMed ID: 21303818
    [No Abstract]   [Full Text] [Related]  

  • 29. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [6th French seminar on drug surveillance. Clermont-Ferrand, 22-23 November 1984].
    Therapie; 1985; 40(5):287-376. PubMed ID: 4095682
    [No Abstract]   [Full Text] [Related]  

  • 31. Notifying patients of adverse drug reactions.
    Pane FJ; Ringer L; Ferguson L; Koshko N
    Am J Hosp Pharm; 1991 Feb; 48(2):236-7. PubMed ID: 2003491
    [No Abstract]   [Full Text] [Related]  

  • 32. Multicenter study of hospital adverse drug reactions.
    Conforti A; Leone R; Moretti U; Sartori M; Velo GP
    Acta Physiol Hung; 1990; 75 Suppl():63-4. PubMed ID: 2196759
    [No Abstract]   [Full Text] [Related]  

  • 33. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 34. Adverse drug reactions in hospital patients.
    Buechner JS
    Med Health R I; 1998 Feb; 81(2):60-1. PubMed ID: 9505068
    [No Abstract]   [Full Text] [Related]  

  • 35. [Necessity and difficulties of quantitative drug monitoring].
    Lagier G; Dally S; Vincens M; Castot A
    Therapie; 1983; 38(3):319-23. PubMed ID: 6612668
    [No Abstract]   [Full Text] [Related]  

  • 36. Adverse drug reaction surveillance in an emergency room.
    Stoukides CA; D'Agostino PR; Kaufman MB
    Am J Hosp Pharm; 1993 Apr; 50(4):712-4. PubMed ID: 8470691
    [No Abstract]   [Full Text] [Related]  

  • 37. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period].
    Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M
    Therapie; 1986; 41(5):375-7. PubMed ID: 3810528
    [No Abstract]   [Full Text] [Related]  

  • 38. Early postmarketing drug safety surveillance: data mining points to consider.
    Hauben M
    Ann Pharmacother; 2004 Oct; 38(10):1625-30. PubMed ID: 15304626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
    Lagier G; Vincens M; Castot A
    Therapie; 1983; 38(3):303-18. PubMed ID: 6612667
    [No Abstract]   [Full Text] [Related]  

  • 40. [Comparative organization of drug monitoring in France and 7 European countries].
    Vaissere J; de Cremiers F; Auriche M; Juillet Y
    Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.